

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set of samples 1</b>														
<b>(81) Digoxin</b>					125									
Samples and groups		[nmol/L]												
<b>Sample A1</b>		1,02	0,21	21	125									
(1) Abbott		0,780	0,12	15	35	0			CRV	1,018	,0100	36%	0,651	1,39
(12) Beckman Coulter		1,12	0,09	8,6	12	0								
(29) Siemens (DPC)		1,06	0,07	6,9	7	0								
(58) Beckman Coulter (Olympus)		1,09	0,10	9,1	11	0								
(60) Roche		1,10	0,16	14	38	0								
(179) Siemens (Bayer)		1,19	0,09	8,3	18	0								
Other					4	0								
									4x 149					
<b>Sample B1</b>		0,842	0,18	22	125				CRV	0,846	,0085	36%	0,541	1,16
(1) Abbott		0,629	0,11	18	35	0								
(12) Beckman Coulter		0,911	0,07	7,9	12	0								
(29) Siemens (DPC)		0,845	0,13	16	7	0								
(58) Beckman Coulter (Olympus)		0,947	0,14	15	11	0								
(60) Roche		0,910	0,14	15	38	0								
(179) Siemens (Bayer)		0,958	0,09	9,5	18	0								
Other					4	0								
									4x 149					
<b>(82) Theophylline</b>					88									
Samples and groups		[µmol/L]												
<b>Sample A1</b>		87,2	5,9	6,7	88				CRV	88,1	0,88	24%	66,9	110
(1) Abbott		85,2	5,8	6,8	24	0								
(12) Beckman Coulter		80,9	6,4	7,9	6	0								
(29) Siemens (DPC)		84,2	7,2	8,6	5	0								
(58) Beckman Coulter (Olympus)		85,0	5,0	5,9	8	0								
(60) Roche		88,2	4,1	4,7	30	0								
(179) Siemens (Bayer)		95,6	7,6	8,0	11	0								
Other					4	0								
									2x 149, 2x 166					
<b>Sample B1</b>		81,4	5,2	6,4	88				CRV	80,99	0,81	24%	61,5	101
(1) Abbott		79,2	4,6	5,8	24	0								
(12) Beckman Coulter		76,0	6,7	8,8	6	0								
(29) Siemens (DPC)		81,6	0,77	0,94	5	0								
(58) Beckman Coulter (Olympus)		80,0	4,7	5,9	8	1								
(60) Roche		82,5	3,0	3,6	30	0								
(179) Siemens (Bayer)		90,2	7,9	8,8	11	0								
Other					4	0								
									2x 149, 2x 166					

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(83) Primidone</b>					8							8	7	88%									0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		19,2	4,1	22	8	CVP	19,2	3,2	24%	14,5	23,9	8	8	100%									0
(999) another manufacturer		19,7	3,4	17	6							6											
Other					2							2											
						1x 60, 1x 998																	
<b>Sample B1</b>		42,6	6,0	14	8	CVP	42,6	4,6	24%	32,3	52,9	8	7	88%									0
(999) another manufacturer		42,6	6,0	14	6							6											
Other					2							2											
						1x 60, 1x 998																	
<b>(84) Phenobarbital</b>					27							27	26	96%									0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		70,3	4,4	6,3	27	CVP	70,3	2,1	20%	56,2	84,4	27	26	96%									0
(1) Abbott		71,0	3,5	4,9	10							10											
(60) Roche		67,7	4,5	6,7	9							9											
Other					8							8											
						2x 58, 1x 75, 1x 149, 4x 999																	
<b>Sample B1</b>		97,7	4,2	4,3	27	CVP	97,7	2,0	20%	78,1	118	27	27	100%									0
(1) Abbott		98,8	3,7	3,7	10							10											
(60) Roche		94,6	2,7	2,9	9							9											
Other					8							8											
						2x 58, 1x 75, 1x 149, 4x 999																	
<b>(85) Phenytoin</b>					46							46	46	100%									0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		83,3	4,1	4,9	46	CVP	83,3	1,5	20%	66,6	100	46	46	100%									0
(1) Abbott		82,8	3,3	4,0	15							15											
(60) Roche		84,7	3,9	4,6	15							15											
Other					16							16											
						2x 12, 3x 29, 3x 58, 1x 75, 1x 149, 2x 179, 4x 999																	
<b>Sample B1</b>		28,0	1,9	6,8	46	CVP	28,0	0,69	20%	22,4	33,6	46	46	100%									0
(1) Abbott		28,3	1,4	5,0	15							15											
(60) Roche		28,5	1,5	5,3	15							15											
Other					16							16											
						2x 12, 3x 29, 3x 58, 1x 75, 1x 149, 2x 179, 4x 999																	
<b>(86) Carbamazepin</b>					64							64	63	98%									0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		39,5	2,7	6,8	64	CVP	39,5	0,82	20%	31,6	47,4	64	63	98%									0
(1) Abbott		38,2	1,2	3,1	19							19											
(29) Siemens (DPC)		34,7	2,7	7,9	6							6											
(60) Roche		39,8	1,5	3,7	20							20											
(179) Siemens (Bayer)		41,8	2,4	5,7	5							5											
Other					14							14											
						3x 12, 4x 58, 1x 75, 2x 149, 4x 999																	
<b>Sample B1</b>		38,6	2,6	6,8	64	CVP	38,6	0,80	20%	30,8	46,4	64	64	100%									0
(1) Abbott		37,4	1,9	5,0	19							19											
(29) Siemens (DPC)		33,6	1,6	4,9	6							6											
(60) Roche		39,1	1,4	3,5	20							20											
(179) Siemens (Bayer)		40,6	1,9	4,6	5							5											

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(86) Carbamazepin</b>	[µmol/L]				64							64	63	98%									0	
Samples and groups																								
<b>Sample B1</b>		38,6	2,6	6,8	64		CVP	38,6	0,80	20%	30,8	46,4	64	64	100%									0
Other					14	0							14											
								3x 12, 4x 58, 1x 75, 2x 149, 4x 999																
<b>(87) Ethosuximide</b>	[µmol/L]				8								8	8	100%									0
Samples and groups																								
<b>Sample A1</b>		361	20	5,4	8		CVP	361	15	24%	274	448	8	8	100%									0
(999) another manufacturer		362	18	5,1	6	0							6											
Other					2	0							2											
								1x 149, 1x 998																
<b>Sample B1</b>		301	27	9,1	8		CVP	301	21	24%	228	374	8	8	100%									0
(999) another manufacturer		301	27	9,1	6	0							6											
Other					2	0							2											
								1x 149, 1x 998																
<b>(88) Valproic acid</b>	[µmol/L]				82								82	80	98%									0
Samples and groups																								
<b>Sample A1</b>		622	49	8,0	82		CVP	622	13	20%	497	747	82	81	99%									0
(1) Abbott		571	24	4,2	23	0							23											
(29) Siemens (DPC)		635	34	5,4	8	0							8											
(58) Beckman Coulter (Olympus)		691	55	7,9	7	0							7											
(60) Roche		635	29	4,6	28	0							28											
(179) Siemens (Bayer)		643	30	4,6	9	0							9											
Other					7	0							7											
								1x 0, 3x 12, 1x 75, 2x 149																
<b>Sample B1</b>		279	28	10	82		CVP	279	7,6	20%	223	335	82	80	98%									0
(1) Abbott		253	11	4,4	23	0							23											
(29) Siemens (DPC)		282	38	13	8	0							8											
(58) Beckman Coulter (Olympus)		309	13	4,3	7	0							7											
(60) Roche		286	17	5,9	28	0							28											
(179) Siemens (Bayer)		298	17	5,7	9	0							9											
Other					7	0							7											
								1x 0, 3x 12, 1x 75, 2x 149																
<b>Set of samples 2</b>																								
<b>(89) Amicacin</b>	[µmol/L]				30								30	27	90%									0
Samples and groups																								
<b>Sample A2</b>		32,0	2,2	7,0	30		CVP	32	1,00	20%	25,6	38,4	30	27	90%									0
(1) Abbott		33,9	0,96	2,8	5	0							5											
(60) Roche		31,4	1,6	5,1	17	0							17											
Other					8	0							8											
								1x 12, 1x 58, 3x 149, 3x 166																
<b>Sample B2</b>		48,2	3,1	6,5	30		CVP	48,2	1,4	20%	38,5	57,9	30	28	93%									0
(1) Abbott		50,0	1,6	3,3	5	0							5											
(60) Roche		47,8	2,5	5,2	17	0							17											
Other					8	0							8											
								1x 12, 1x 58, 3x 149, 3x 166																

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/18 - Therapeutic Drugs

Dead line: 13.04.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(90) Gentamicin</b>					55							55	51	93%									0
Samples and groups	[µmol/L]																						
<b>Sample A2</b>		7,66	0,88	11	55	CVP	7,66	0,29	31%	5,28	10,1	55	52	95%									0
(1) Abbott		7,92	0,50	6,4	19							19											
(60) Roche		6,83	1,6	23	20							20											
(179) Siemens (Bayer)		7,88	0,60	7,6	8							8											
Other					8							8											
							1x 0, 3x 12, 3x 58, 1x 149																
<b>Sample B2</b>		15,6	2,9	19	55	CVP	15,6	0,97	31%	10,7	20,5	55	52	95%									0
(1) Abbott		16,6	1,2	7,1	19							19											
(60) Roche		13,3	2,6	19	20							20											
(179) Siemens (Bayer)		17,4	3,9	22	8							8											
Other					8							8											
							1x 0, 3x 12, 3x 58, 1x 149																
<b>(92) Vankomycin</b>					58							58	55	95%									0
Samples and groups	[µmol/L]																						
<b>Sample A2</b>		11,0	1,5	13	58	CVP	11	0,47	28%	7,92	14,1	58	56	97%									0
(1) Abbott		11,0	0,70	6,4	21							21											
(60) Roche		12,1	1,4	12	22							22											
(179) Siemens (Bayer)		8,94	0,57	6,4	9							9											
Other					6							6											
							1x 0, 2x 12, 1x 58, 2x 149																
<b>Sample B2</b>		28,8	4,0	14	58	CVP	28,8	1,3	28%	20,7	36,9	58	56	97%									0
(1) Abbott		28,4	1,9	6,6	21							21											
(60) Roche		31,5	4,3	14	22							22											
(179) Siemens (Bayer)		24,0	1,8	7,4	9							9											
Other					6							6											
							1x 0, 2x 12, 1x 58, 2x 149																
<b>(93) Methotrexate</b>					13							13	12	92%									0
Samples and groups	[µmol/L]																						
<b>Sample A2</b>		0,799	0,04	5,8	13	CVP	0,799	0,031	30%	0,559	1,04	13	12	92%									0
(1) Abbott		0,784	0,03	4,9	8							8											
Other					5							5											
							1x 60, 1x 126, 1x 998, 2x 999																
<b>Sample B2</b>		2,79	0,40	14	13	CVP	2,79	0,27	30%	1,95	3,63	13	12	92%									0
(1) Abbott		2,76	0,30	11	8							8											
Other					5							5											
							1x 60, 1x 126, 1x 998, 2x 999																

st\_kn\_np

End of report

Printed: 18.04.2018